CN105770799A - 一种具有改善脑部记忆功能的颗粒制剂 - Google Patents
一种具有改善脑部记忆功能的颗粒制剂 Download PDFInfo
- Publication number
- CN105770799A CN105770799A CN201610131713.0A CN201610131713A CN105770799A CN 105770799 A CN105770799 A CN 105770799A CN 201610131713 A CN201610131713 A CN 201610131713A CN 105770799 A CN105770799 A CN 105770799A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- mixed powder
- granular preparation
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 210000004556 brain Anatomy 0.000 title claims abstract description 20
- 230000006870 function Effects 0.000 title claims abstract description 13
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 25
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 claims abstract description 13
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 13
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 13
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 claims abstract description 13
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 13
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 13
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940106134 krill oil Drugs 0.000 claims abstract description 13
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 13
- 229940016667 resveratrol Drugs 0.000 claims abstract description 13
- 229960003080 taurine Drugs 0.000 claims abstract description 13
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims abstract description 13
- 229940068475 zinc citrate Drugs 0.000 claims abstract description 13
- 235000006076 zinc citrate Nutrition 0.000 claims abstract description 13
- 239000011746 zinc citrate Substances 0.000 claims abstract description 13
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 12
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 12
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 12
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims abstract description 11
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims abstract description 11
- 241000233866 Fungi Species 0.000 claims abstract description 11
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 11
- 235000008397 ginger Nutrition 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 10
- 229940046009 vitamin E Drugs 0.000 claims abstract description 10
- 239000011709 vitamin E Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000011812 mixed powder Substances 0.000 claims description 48
- 238000005303 weighing Methods 0.000 claims description 17
- 241000195493 Cryptophyta Species 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 239000007779 soft material Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 241000234282 Allium Species 0.000 claims description 10
- 241001092040 Crataegus Species 0.000 claims description 10
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 10
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 10
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 10
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 10
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 10
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 10
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 10
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 10
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 10
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 10
- 241000234314 Zingiber Species 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 abstract description 13
- 230000036541 health Effects 0.000 abstract description 5
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 230000008344 brain blood flow Effects 0.000 abstract description 3
- 244000291564 Allium cepa Species 0.000 abstract 1
- 240000002900 Arthrospira platensis Species 0.000 abstract 1
- 235000016425 Arthrospira platensis Nutrition 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 229940082787 spirulina Drugs 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000003925 brain function Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000004126 nerve fiber Anatomy 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000006386 memory function Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000221377 Auricularia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000009692 xuesetong Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于营养保健领域,涉及一种具有改善脑部记忆功能的颗粒制剂。该颗粒制剂由山楂、生姜、洋葱、黑木耳、白藜芦醇、磷脂酰丝氨酸、藻油DHA粉、磷虾油粉、牛磺酸、柠檬酸锌、神经酸、维生素E、异麦芽酮糖、麦芽糊精组成。该颗粒制剂采用传统中医养生之道,结合现代营养学,配方合理,食用简单,用水冲服即可达到改善脑部血液循环和记忆的功效,也可灌制胶囊和压制成片剂。
Description
技术领域
本发明涉及营养保健领域,特别涉及一种具有改善脑部记忆功能的颗粒制剂。
背景技术
脑部是人类最为精密的器官,人类一切的生命活动都与脑部无法分隔。然而,随着年龄的增大,身体的老化,使得脑部功能开始下降。由于脑部功能下降引起的一个重要症状就是记忆力下降以及衰退。现代生物学研究指出,记忆是通过神经系统一系列生理、生化和组织学可逆性变化而实现的。所以脑的正常记忆功能取决于足够数量的脑神经细胞及神经肽。记忆力衰退需要采取积极的预防及控制措施,以防人体由记忆力衰退状态向疾病特别是慢性疾病方向的转化。
据研究报道,造成脑部功能衰退的原因主要有:(1)血液粘稠度增高,血液缓慢,营养吸收差;(2)大脑神经细胞衰退,细胞合成和功能发挥过程中的基础成分缺失;(3)脑部过氧化物质沉积过多,影响脑部功能发挥。
就目前而言,临床上主要会采用氟桂利嗪、尼莫地平片、血塞通、丹参片、脑灵素片、银杏胶囊等西药或是中药来进行脑部血液循环不良以及记忆衰退的治疗。但是,长期服用这些药品或多或少会产品胸闷、心悸、食欲不佳等不良反应,长期以往会严重影响生活质量。进一步地,大部分人群还未达到需要服用药品的地步,但又不能放任不管,故缺少相应的日常保健调理产品。
发明内容
有鉴于此,本发明的目的在于提供一种具有改善脑部记忆功能的颗粒制剂,该颗粒制剂采用传统中医养生之道,结合现代营养学,配方合理,食用简单,用水冲服即可达到改善脑部血液循环和记忆的功效,也可灌制胶囊和压制成片剂。
为实现上述目的,本发明提供如下技术方案:
一种具有改善脑部记忆功能的颗粒制剂,由山楂、生姜、洋葱、黑木耳、白藜芦醇、磷脂酰丝氨酸、藻油DHA粉、磷虾油粉、牛磺酸、柠檬酸锌、神经酸、维生素E、异麦芽酮糖、麦芽糊精组成。
其中,
山楂:化血块,气块,活血,降低高脂血。
生姜:性散,能散风邪,通畅神明,助生发之气。
洋葱:有助于防治导致动脉壁变厚的特定慢性炎症。
黑木耳:滋润强壮,清肺益气,补血活血,能减低血液凝块,缓和冠状动脉粥样硬化。
白藜芦醇:具有极强的抗氧化能力,能够清除自由基和减缓血栓。
磷脂酰丝氨酸:改善神经细胞功能,调节神经脉冲传导,增进记忆功能。
藻油DHA粉:大脑细胞膜的重要构成成分,参与脑细胞的形成和发育。
磷虾油粉:富含氨基酸和不饱和脂肪酸,保护神经细胞膜,增强记忆力。
牛磺酸:增强神经细胞中酶的活性,促进神经系统生长发育、增殖分化。
柠檬酸锌:从复制和转录水平影响神经肽SS的合成。
神经酸:能完整通透过血脑屏障,直接作用于神经纤维进行修复疏通,让受损、脱落的保护鞘再生,溶解堵塞通道的坏死组织,诱导神经纤维的自我生长及分裂,使神经细胞所产生的信息及外界的信息都能顺利通过神经纤维传递,达到指令畅通,以此激活受损、病变及休眠的神经细胞,重塑神经网络,改善脑部衰退以及记忆衰退。
维生素E:具有较强的抗氧化作用,能够改善血液脂代谢,提升脑部血管韧性,改善其循环,并能保护大脑细胞膜。
异麦芽酮、麦芽糊精:作为颗粒制剂的辅料,保证制剂工艺成型。
本发明的优选技术方案为:
一种具有改善脑部记忆功能的颗粒制剂按重量份数包括以下成分:山楂300-600份、生姜300-600份、洋葱300-600份、黑木耳300-600份、白藜芦醇30-50份、磷脂酰丝氨酸150-300份、藻油DHA粉100-150份、磷虾油粉80-120份、牛磺酸150-300份、柠檬酸锌30-60份、神经酸50-100份、维生素E5-10份、异麦芽酮糖500-800份、麦芽糊精80-150份。
本发明还提供上述颗粒制剂的制备方案为:
步骤1、称取山楂、生姜、洋葱、黑木耳,加10倍量纯净水,100℃回流提取3小时,将提取液过滤、喷雾干燥得混合粉1,将残渣干燥、以80目粒径粉碎得混合粉2。
步骤2、称取白藜芦醇、磷脂酰丝氨酸、藻油DHA粉、磷虾油粉、牛磺酸、柠檬酸锌、神经酸、维生素E,混合均匀,得混合粉3;
步骤3、称取异麦芽酮糖、麦芽糊精,加入混合粉1、混合粉2、混合粉3,混合均匀,得混合粉4;
步骤4、以40%-60%浓度的乙醇溶液作为润湿剂,将混合粉4制软材;
步骤5、将步骤4中制得的软材制粒、干燥、整粒,即得。
本发明的颗粒制剂可以直接用水冲泡饮用,也可灌装制成胶囊剂,更可进一步加入4-6重量份的硬脂酸镁压制成片剂。
本发明具有以下优点及有益效果:
(1)该颗粒制剂利用山楂、生姜、洋葱、黑木耳、白藜芦醇、维生素E的“疏通”作用,降低脑部血管中的血脂浓度,清除血管中垃圾和脑部沉积的过氧化物质,提升血液循环流通性,增加有效物质在脑部血管的流通与吸收,提升脑部功能。
(2)该颗粒制剂利用磷脂酰丝氨酸、藻油DHA粉、磷虾油粉、牛磺酸、柠檬酸锌、神经酸的“补实”作用,从脑神经细胞的生成、发育、稳定以及功能发挥等各个阶段和层次补益与调理,提升脑部记忆功能。
(3)该颗粒制剂利用“疏通”和“补实”两个方面协同并效,突破了现有技术和产品中成分少,功效单一,而且具有副作用的技术缺陷;进一步地,该颗粒制剂食用方便,仅需要用水冲泡即可饮用并发挥功效,还能制备胶囊和片剂,应用面广泛。
具体实施例
本发明公开了一种具有改善脑部记忆功能的颗粒制剂,本领域技术人员可以借鉴本文内容,适当改进参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明所述检测方法已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明。
为更好地阐述本发明,以下将通过具体的实施例进行说明。
实施例1:
1、称取山楂3000g、生姜3000g、洋葱3000g、黑木耳3000g,加10倍量纯净水,100℃回流提取3小时,将提取液过滤、喷雾干燥得混合粉1,将残渣干燥、以80目粒径粉碎得混合粉2。
2、称取白藜芦醇300g、磷脂酰丝氨酸1500g、藻油DHA粉1000g、磷虾油粉800g、牛磺酸1500g、柠檬酸锌300g、神经酸500g、维生素E50g,混合均匀,得混合粉3;
3、称取异麦芽酮糖5000g、麦芽糊精800g,加入混合粉1、混合粉2、混合粉3,混合均匀,得混合粉4;
4、以40%浓度的乙醇溶液作为润湿剂,将混合粉4制软材;
5、将步骤4中制得的软材制粒、干燥、整粒,即得。
实施例2:
1、称取山楂6000g、生姜6000g、洋葱6000g、黑木耳6000g,加10倍量纯净水,100℃回流提取3小时,将提取液过滤、喷雾干燥得混合粉1,将残渣干燥、以80目粒径粉碎得混合粉2。
2、称取白藜芦醇500g、磷脂酰丝氨酸3000g、藻油DHA粉1500g、磷虾油粉1200g、牛磺酸3000g、柠檬酸锌600g、神经酸1000g、维生素E100g,混合均匀,得混合粉3;
3、称取异麦芽酮糖8000g、麦芽糊精1500g,加入混合粉1、混合粉2、混合粉3,混合均匀,得混合粉4;
4、以60%浓度的乙醇溶液作为润湿剂,将混合粉4制软材;
5、将步骤4中制得的软材制粒、干燥、整粒,即得。
实施例3:
1、称取山楂5000g、生姜5000g、洋葱5000g、黑木耳5000g,加10倍量纯净水,100℃回流提取3小时,将提取液过滤、喷雾干燥得混合粉1,将残渣干燥、以80目粒径粉碎得混合粉2。
2、称取白藜芦醇400g、磷脂酰丝氨酸2000g、藻油DHA粉1200g、磷虾油粉1000g、牛磺酸2000g、柠檬酸锌400g、神经酸700g、维生素E70g,混合均匀,得混合粉3;
3、称取异麦芽酮糖7000g、麦芽糊精1300g,加入混合粉1、混合粉2、混合粉3,混合均匀,得混合粉4;
4、以50%浓度的乙醇溶液作为润湿剂,将混合粉4制软材;
5、将步骤4中制得的软材制粒、干燥、整粒,即得。
6、将步骤5中制得的颗粒,加入80g硬脂酸镁,压片,即得本发明所述片剂产品。
实施例4:
1、称取山楂4000g、生姜4000g、洋葱4000g、黑木耳4000g,加10倍量纯净水,100℃回流提取3小时,将提取液过滤、喷雾干燥得混合粉1,将残渣干燥、以80目粒径粉碎得混合粉2。
2、称取白藜芦醇400g、磷脂酰丝氨酸2000g、藻油DHA粉1200g、磷虾油粉1000g、牛磺酸2000g、柠檬酸锌500g、神经酸750g、维生素E75g,混合均匀,得混合粉3;
3、称取异麦芽酮糖6000g、麦芽糊精1200g,加入混合粉1、混合粉2、混合粉3,混合均匀,得混合粉4;
4、以50%浓度的乙醇溶液作为润湿剂,将混合粉4制软材;
5、将步骤4中制得的软材制粒、干燥、整粒,即得。
6、将步骤5中制得的颗粒,灌入硬胶囊,即得本发明所述胶囊剂产品。
实施例5:
将实施例1-3制备所得制剂按照《保健食品检验与评价技术规范(2003版)》进行改善记忆的动物试验。下表为试验数据:
★实施例组与对照组相比具有显著差异。
由上述结果可以看出,根据《保健食品检验与评价技术规范(2003版)》修订版标准判断,证明实施例1-3所得颗粒制剂具有改善动物记忆功能。
实施例6:
将实施例1-3制备所得制剂进行改善记忆的临床试验,结果如下:
▲实施例组在服用前后具有显著差异。
由上述结果可以看出,根据《保健食品检验与评价技术规范(2003版)》修订版标准判断,证明实施例1-3所得颗粒制剂具有改善人体记忆功能。
综上所述,本发明颗粒制剂具有改善脑部记忆的功能。
以上所述仅是本发明的特定实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (4)
1.一种具有改善脑部记忆功能的颗粒制剂,其特征在于,所述颗粒制剂由山楂、生姜、洋葱、黑木耳、白藜芦醇、磷脂酰丝氨酸、藻油DHA粉、磷虾油粉、牛磺酸、柠檬酸锌、神经酸、维生素E、异麦芽酮糖、麦芽糊精组成。
2.根据权利要求1中所述的颗粒制剂,其特征在于,所述颗粒制剂按重量份数的组成为山楂300-600份、生姜300-600份、洋葱300-600份、黑木耳300-600份、白藜芦醇30-50份、磷脂酰丝氨酸150-300份、藻油DHA粉100-150份、磷虾油粉80-120份、牛磺酸150-300份、柠檬酸锌30-60份、神经酸50-100份、维生素E5-10份、异麦芽酮糖500-800份、麦芽糊精80-150份。
3.根据权利要求1中所述的颗粒制剂,其特征在于,所述颗粒制剂的制备方法包括以下步骤:
步骤1、称取山楂、生姜、洋葱、黑木耳,加10倍量纯净水,100℃回流提取3小时,将提取液过滤、喷雾干燥得混合粉1,将残渣干燥、以80目粒径粉碎得混合粉2;
步骤2、称取白藜芦醇、磷脂酰丝氨酸、藻油DHA粉、磷虾油粉、牛磺酸、柠檬酸锌、神经酸、维生素E,混合均匀,得混合粉3;
步骤3、称取异麦芽酮糖、麦芽糊精,加入混合粉1、混合粉2、混合粉3,混合均匀,得混合粉4;
步骤4、以40%-60%浓度的乙醇溶液作为润湿剂,将混合粉4制软材;
步骤5、将步骤4中制得的软材制粒、干燥、整粒,即得。
4.根据权利要求1-3任一项所述的颗粒制剂,其特征在于,所述颗粒制剂也可灌装制成胶囊剂,更可进一步加入4-6重量份的硬脂酸镁压制成片剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610131713.0A CN105770799A (zh) | 2016-03-09 | 2016-03-09 | 一种具有改善脑部记忆功能的颗粒制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610131713.0A CN105770799A (zh) | 2016-03-09 | 2016-03-09 | 一种具有改善脑部记忆功能的颗粒制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105770799A true CN105770799A (zh) | 2016-07-20 |
Family
ID=56387310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610131713.0A Withdrawn CN105770799A (zh) | 2016-03-09 | 2016-03-09 | 一种具有改善脑部记忆功能的颗粒制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105770799A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107594268A (zh) * | 2017-08-04 | 2018-01-19 | 杨宇明 | 一种健脑安神抗焦虑的神经酸复方饮料及其制备方法 |
CN107997155A (zh) * | 2017-12-01 | 2018-05-08 | 北京斯利安药业有限公司 | 一种组合物、其应用和抗氧化、改善记忆力的产品 |
CN108669561A (zh) * | 2018-07-20 | 2018-10-19 | 李明龙 | 一种预防治疗神经系统疾病的产品及其制备方法和应用 |
CN109106738A (zh) * | 2018-09-12 | 2019-01-01 | 沈阳高名医药科技有限公司 | 一种神经酸组合物及其在神经保护中的应用 |
CN110547465A (zh) * | 2019-08-06 | 2019-12-10 | 上海麒稷健康科技有限公司 | 一种大脑神经营养组合物及制备方法 |
CN113892575A (zh) * | 2021-10-26 | 2022-01-07 | 杨继洲(上海)健康科技有限公司 | 一种增强神经生长与修复的固体饮料及其制备方法 |
CN114176222A (zh) * | 2021-11-18 | 2022-03-15 | 山东省药学科学院 | 一种辅助改善记忆的营养组合物及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101766660A (zh) * | 2008-12-30 | 2010-07-07 | 安琪酵母股份有限公司 | 一种具有改善记忆功能的制剂、其制备方法及其应用 |
CN103690627A (zh) * | 2013-11-20 | 2014-04-02 | 程刚 | 一种辅助改善记忆保健功能冲剂 |
CN103829227A (zh) * | 2012-11-21 | 2014-06-04 | 李华 | 一种辅助改善记忆功能的胶囊食品 |
CN104547264A (zh) * | 2014-12-22 | 2015-04-29 | 山东天地健生物工程有限公司 | 一种改善记忆力的胶囊及其制备方法 |
CN105267239A (zh) * | 2014-06-30 | 2016-01-27 | 北京斯利安制药有限公司 | 一种改善记忆和补充钙的藻油dha和钙的混合制剂产品 |
CN105341909A (zh) * | 2015-11-09 | 2016-02-24 | 苏州泽达兴邦医药科技有限公司 | 一种用于改善记忆力的保健食品及制作方法 |
-
2016
- 2016-03-09 CN CN201610131713.0A patent/CN105770799A/zh not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101766660A (zh) * | 2008-12-30 | 2010-07-07 | 安琪酵母股份有限公司 | 一种具有改善记忆功能的制剂、其制备方法及其应用 |
CN103829227A (zh) * | 2012-11-21 | 2014-06-04 | 李华 | 一种辅助改善记忆功能的胶囊食品 |
CN103690627A (zh) * | 2013-11-20 | 2014-04-02 | 程刚 | 一种辅助改善记忆保健功能冲剂 |
CN105267239A (zh) * | 2014-06-30 | 2016-01-27 | 北京斯利安制药有限公司 | 一种改善记忆和补充钙的藻油dha和钙的混合制剂产品 |
CN104547264A (zh) * | 2014-12-22 | 2015-04-29 | 山东天地健生物工程有限公司 | 一种改善记忆力的胶囊及其制备方法 |
CN105341909A (zh) * | 2015-11-09 | 2016-02-24 | 苏州泽达兴邦医药科技有限公司 | 一种用于改善记忆力的保健食品及制作方法 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107594268A (zh) * | 2017-08-04 | 2018-01-19 | 杨宇明 | 一种健脑安神抗焦虑的神经酸复方饮料及其制备方法 |
CN107997155A (zh) * | 2017-12-01 | 2018-05-08 | 北京斯利安药业有限公司 | 一种组合物、其应用和抗氧化、改善记忆力的产品 |
CN107997155B (zh) * | 2017-12-01 | 2021-05-11 | 北京斯利安药业有限公司 | 一种组合物、其应用和抗氧化、改善记忆力的产品 |
CN108669561A (zh) * | 2018-07-20 | 2018-10-19 | 李明龙 | 一种预防治疗神经系统疾病的产品及其制备方法和应用 |
CN109106738A (zh) * | 2018-09-12 | 2019-01-01 | 沈阳高名医药科技有限公司 | 一种神经酸组合物及其在神经保护中的应用 |
CN110547465A (zh) * | 2019-08-06 | 2019-12-10 | 上海麒稷健康科技有限公司 | 一种大脑神经营养组合物及制备方法 |
CN113892575A (zh) * | 2021-10-26 | 2022-01-07 | 杨继洲(上海)健康科技有限公司 | 一种增强神经生长与修复的固体饮料及其制备方法 |
CN114176222A (zh) * | 2021-11-18 | 2022-03-15 | 山东省药学科学院 | 一种辅助改善记忆的营养组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105770799A (zh) | 一种具有改善脑部记忆功能的颗粒制剂 | |
JP6873517B2 (ja) | 成年女性、高齢者及び亜健康状態の人々に適用できる健康保持製品組成物 | |
CN108850366A (zh) | 一种具有降尿酸作用的代用茶组合物及其制备方法 | |
KR101870846B1 (ko) | 다기능성 조성물 및 이의 제조 방법과 용도 | |
Kochhar et al. | Effect of supplementation of traditional medicinal plants on blood glucose in non–insulin-dependent diabetics: A pilot study | |
CN104257887B (zh) | 一种促进排铅的组合物及其应用 | |
CN107319525A (zh) | 一种减肥减脂专用型临床营养配方及其制备方法 | |
CN103549415B (zh) | 一种具有缓解疲劳、补肾壮阳功效的生物中药配方组合物、中药制剂、制备方法及其用途 | |
CN102349608B (zh) | 一种清咽润喉的保健品组合物及其制备方法 | |
CN1966031A (zh) | 预防与治疗衰老病的药物 | |
CN107183290A (zh) | 一种黑枸杞压片糖果及其制备方法 | |
CN108743500A (zh) | 既可内服又可外用的美容养颜复方肽功能食品及其制备方法 | |
CN106421757A (zh) | 一种辅助治疗痛风和增加骨密度的组合物及其应用 | |
CN106942578A (zh) | 一种控制嘌呤摄入及促进尿酸排泄的天然膳食 | |
CN105943958A (zh) | 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 | |
CN111467468A (zh) | 一种含人参、蛹虫草、生姜、枸杞子浓缩营养液及其制备方法 | |
CN101647820B (zh) | 活性纯蛇粉胶囊及其制作工艺 | |
CN103830280B (zh) | 一种螺旋藻提取物的制备方法 | |
CN110679815A (zh) | 一种具有抗疲劳和耐缺氧功能的药食同源复合保健饮料及其制备方法 | |
CN110227095A (zh) | 一种降尿酸组合物及其制备方法 | |
CN101336705B (zh) | 保健食品及其制备方法 | |
CN105995980B (zh) | 一种具有体重管理作用的组合物及其制备方法 | |
WO2019100843A1 (zh) | 一种浒苔多糖复合降血脂保健品及其制备方法 | |
CN112089792A (zh) | 一种净颜膏及其制备方法 | |
KR101093006B1 (ko) | 미생물을 이용한 우황 청심원 원료 함유 건강식품의 제조방법 및 그 제조방법에 의해 제조된 건강식품 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160720 |